Aptamer Technology

Aptamer Technology utilises short single stranded DNA or RNA oligonucleotides that fold into specific three dimensional structures capable of binding target molecules with high affinity and specificity through shape complementarity rather than Watson Crick base pairing. These synthetic alternatives to antibodies, sometimes termed 'chemical antibodies,' emerge from iterative in vitro selection processes called SELEX (Systematic Evolution of Ligands by Exponential Enrichment) that screen vast molecular libraries to identify sequences recognising virtually any target including proteins, small molecules, and cells.

The biopharmaceutical sector increasingly recognises aptamers as versatile therapeutic and diagnostic tools offering distinct advantages over traditional antibodies including smaller size enabling better tissue penetration, chemical synthesis allowing reproducible manufacturing at lower costs, minimal immunogenicity, and rapid development timelines. Therapeutic aptamers have achieved regulatory approval for conditions like age related macular degeneration, demonstrating clinical viability. Beyond therapeutics, aptamers serve as powerful research tools, diagnostic reagents, and drug delivery vehicles capable of targeted payload transport. Development challenges include optimising in vivo stability through chemical modifications, enhancing cellular uptake, and extending circulation half life through polyethylene glycol conjugation or other strategies. Companies pursuing aptamer platforms invest in proprietary selection technologies, chemical modification strategies, and formulation approaches that enhance performance characteristics. The technology proves particularly valuable for difficult targets lacking suitable antibody solutions and enables rapid response to emerging disease threats. As nucleic acid therapeutics advance and manufacturing capabilities mature, aptamer technology expands its therapeutic footprint while offering innovative solutions across drug discovery and precision medicine applications.